Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.

Fien A von MeijenfeldtSebastian HavervallJelle AdelmeijerAnnika LundströmAnn-Sofie RudbergMaria MagnussonNigel MackmanCharlotte ThalinJ P Luyendyk

Published in: Research and practice in thrombosis and haemostasis (2020)

Severe COVID-19 is associated with prothrombotic changes with increased in vivo activation of coagulation and fibrinolysis, despite anticoagulant therapy.

Keyphrases

coronavirus disease
sars cov
atrial fibrillation
venous thromboembolism
cardiovascular events
early onset
risk factors
stem cells
type diabetes
mesenchymal stem cells
cardiovascular disease
drug induced
cell therapy